No abstract

Objective The use of many antiseizure medications (ASMs) is limited due to pharmacoresistance and dose‐limiting side effects, suggesting an unmet need for novel therapeutic approaches. The neuropeptide galanin reduces seizures in several preclinical seizure and epilepsy models, but its clinical utility is limited due to rapid metabolism and poor blood–brain barrier penetration. The lead galanin analog 810–2 is systemically bioavailable and reduces seizures when administered alone. Further development of this analog, with the potential for use as an add‐on therapy in patients with epilepsy, requires a better understanding of the use of this analog in combination with approved ASMs. We sought to evaluate 810–2 in combination with commonly used ASMs in rodent models of seizures. Methods The mouse 6‐Hz seizure assay was used to test efficacy of 810–2 in combination with levetiracetam (LEV), valproic acid (VPA), or lacosamide (LCM) using a 1:1 dose ratio in isobolographic studies. Further characterization was performed for the combination of 810–2 and LEV in the mouse corneal kindling and rat 6‐Hz assays. Results Whereas the combination of 810–2 with VPA and LCM yielded additive interactions, the combination of 810–2 with LEV demonstrated a synergistic interaction in the mouse 6‐Hz assay. Supra‐additive effects were also observed in the mouse corneal kindling and rat 6‐Hz assays for this combination. Significance The combination of 810–2 with LEV suggests the potential for this galanin analog to be further developed as an add‐on therapy for patients with epilepsy, particularly when coadministered with LEV.